Lactobacillus rhamnosus LRa05 and Improved H Pylori Eradication Rates

Doses used in studies

CFU/day: 10 billion (median 10 billion, IQR 10 billion–10 billion) — 1 study

Time to effect

Median: 4 weeks · IQR 4 weeks–4 weeks · Range 4 weeks–4 weeks — Reported in 1 of 1 study

Safety in these studies

Overall tolerabilityReported
Although LRa05 did not significantly improve the success rate of H. pylori eradication therapy, it has the potential to improve liver function and reduced levels of inflammatory markers such as IL-6 and TNF-α in the body, regulating the inflammatory response. In addition, it played a positive role in alleviating the adverse symptoms and gut microbiota disturbances caused by eradication therapy, providing a possible way to improve the overall health of patients and demonstrating promising clinical potential.
from: Evaluation of efficacy and safety of Lacticaseibacillus rhamnosus LRa05 in the eradication
abdominal painReported
GSRS symptom scores showed that LRa05 alleviated abdominal pain, acid reflux, bloating, and diarrhea, enhancing patient compliance.
from: Evaluation of efficacy and safety of Lacticaseibacillus rhamnosus LRa05 in the eradication
acid refluxReported
GSRS symptom scores showed that LRa05 alleviated abdominal pain, acid reflux, bloating, and diarrhea, enhancing patient compliance.
from: Evaluation of efficacy and safety of Lacticaseibacillus rhamnosus LRa05 in the eradication
bloatingReported
GSRS symptom scores showed that LRa05 alleviated abdominal pain, acid reflux, bloating, and diarrhea, enhancing patient compliance.
from: Evaluation of efficacy and safety of Lacticaseibacillus rhamnosus LRa05 in the eradication
diarrheaReported
GSRS symptom scores showed that LRa05 alleviated abdominal pain, acid reflux, bloating, and diarrhea, enhancing patient compliance.
from: Evaluation of efficacy and safety of Lacticaseibacillus rhamnosus LRa05 in the eradication

1 of 1 paper

Evaluation of efficacy and safety of Lacticaseibacillus rhamnosus LRa05 in the eradication of Helicobacter pylori: a randomized, double-blind, placebo-controlled trial.
- 2024-08-21
- RCT
- Frontiers in immunology 15
- - Yue Niu
  - Jing Li
  - Hongwei Qian
  - Chunli Liang
  - Xinyi Shi
  - Shurui Bu
- PubMed: 39234246
- DOI: 10.3389/fimmu.2024.1450414
12 Insights on
- Improved H Pylori Eradication Rates
- High evidence
- Clinical
The LRa05 group exhibited a trend toward higher H. pylori eradication rates (86.11%) compared to the placebo group (82.86%), though the difference was not statistically significant.
Effect
Neutral
Effect size
Small
Significant
No
Dose
1 × 10^10 CFU/day for 4 weeks

Lactobacillus rhamnosus LRa05 and Improved H Pylori Eradication Rates

Evaluation of efficacy and safety of Lacticaseibacillus rhamnosus LRa05 in the eradication of Helicobacter pylori: a randomized, double-blind, placebo-controlled trial.